METABOLIC / SINGLE
SURVODUTIDE
10MGThis content is intended for educational and research reference only and does not constitute medical advice, diagnosis, or treatment. Experimental compounds are for research use only and are not for human consumption. Always consult qualified healthcare providers before starting any therapy.
Research Overview
A dual GLP-1/glucagon receptor agonist studied in metabolic and weight-management research.
Available Strengths
- 10MG (SUR10)
Research Protocol
Reference titration schedule
| Period | Dose | U-100 units | Volume |
|---|---|---|---|
| Weeks 1–2 | 0.6 mg | 12 | 0.12 mL |
| Weeks 3–4 | 1.2 mg | 24 | 0.24 mL |
| Weeks 5–6 | 1.8 mg | 36 | 0.36 mL |
| Weeks 7–8 | 2.4 mg | 48 | 0.48 mL |
| Weeks 9–10 | 3.6 mg | 72 | 0.72 mL |
| Weeks 11–12 | 4.8 mg | 96 | 0.96 mL |
Reconstitution
5.0 mg/mL once reconstituted
- Draw 2.0 mL of bacteriostatic water per 10 mg vial.
- Inject slowly along the vial wall; swirl gently until dissolved.
Research context
The GLP-1 component is studied for enhancing satiety while the glucagon component is linked to increased energy expenditure and hepatic lipid oxidation in the cited research.
Storage
≤−20°C, minimize moisture. 2–8°C, protected from light, avoid freeze-thaw cycles.
Research Notes
- For educational and research reference only. Not medical advice and not intended for unsupervised human use.
- The final titration step (6.0 mg) exceeds standard 1 mL syringe capacity in the reference table and would require splitting across two injections.
References
Source reference: PeptideDosages.com · 2026-08-18 · Exact strength match with the cited source